Abstract
As a result of research it was succeeded to receive the model of non-alcoholic steatohepatitis which is characterized by obesity, violation of the structural organization, a fabric necrosis, formation of fibrosis of a liver. The developed model of non-alcoholic steatohepatitis allows to study also staging of development of a fatty desease of the liver which is characterized by formation of a steatogepatitis and fibrosis. In quality the inducing factors the high-fat diet and antibiotics were used. The offered NASH model can be used in the field of chronic experiments for an assessment of extent of violation of a functional condition of hepatobiliary system and for search of the effective pharmacotheurapeutichepatoprotective agents.
Highlights
Nonalcoholic steatohepatitis (NASH) is a liver disease, characterized by a histologic similarity with an alcoholic liver disease, which occurs in people who do not consume a significant quantity of alcohol
NASH is the hepatic manifestation of metabolic syndrome that is characterized by steatosis, inflammation, and fibrosis, and may progress to cirrhosis and carcinoma (Chen, et al.2008; Polesel et al.2009;Yun et al, 2013)
As a result of the conducted research it is revealed that the keeping of animals on a fatty diet with application of a tetracycline leads to change of a number of the studied weight parameters
Summary
Nonalcoholic steatohepatitis (NASH) is a liver disease, characterized by a histologic similarity with an alcoholic liver disease, which occurs in people who do not consume a significant quantity of alcohol NASH is believed to be one of the most common explanations for abnormal liver chemistries in adults (Attar et al, 2013). NASH is the hepatic manifestation of metabolic syndrome that is characterized by steatosis, inflammation, and fibrosis, and may progress to cirrhosis and carcinoma (Chen, et al.2008; Polesel et al.2009;Yun et al, 2013). Risk factors for NASH include obesity, type II diabetes, hyperlipidemia, total parenteral nutrition, and the use of certain drugs, includingantibiotics (Pries et al, 2008; Praveen et al, 2012). The identification of fatty liver on imaging studies supports the diagnosis of NASH, which can be established definitively by liver biopsy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
